https:/#/nc.emagedd.www/

Články časopisu Diagnosis of gastrointestinal motility disorders

Author of the article: Jana Koželuhová, Karel Balihar, Lucie Zdrhová Source: Vnitřní lékařství | 6/2018 14. 9. 2018

Články časopisu A complex view of vitamin B₁₂ deficiency in childhood

Author of the article: K. Brennerová, K. Juríčková, C. Šebová, M. Ostrožlíková, J. Hornová, M. Kolníková, V. Bzdúch Source: Česko-slovenská pediatrie | 6/2018 11. 10. 2018

Články časopisu Achalasia –⁠ position of surgery in current management

Author of the article: M. Stašek, Č. Neoral, R. Vrba, R. Aujeský, Dušan Klos Source: Rozhledy v chirurgii | 4/2022 8. 5. 2022

Články časopisu Respiratory syncytial virus (RSV) infection among infants in the first year of life (Czech Republic, 2017–2022)

Author of the article: P. Pazdiora, O. Šanca Source: Epidemiologie, mikrobiologie, imunologie | 2/2024 24. 4. 2024

News Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition

More than 7 years –⁠ that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.

Source: Genetic Profile and Treatment of NSCLC 6. 12. 2022

News New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy

Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.

Source: Acute Myeloid Leukemia 10. 5. 2024

News Can Erdostein Help in Treating Infections Related to Biofilm Formation?

One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a biofilm? Which bacteria are likely to form it, and how can erdostein help in the fight against it?

Source: Cough Therapy 8. 4. 2022

News Update of International Recommendations for the Diagnosis and Treatment of Hereditary Angioedema from 2021

The aim of the 2021 update of the recommendations for the diagnosis and treatment of hereditary angioedema (HAE) is to help doctors answer important clinical questions: How to diagnose HAE? When and what prophylactic treatment to administer? What are the treatment goals? How do treatment of children and pregnant women differ? How to monitor disease activity, its impact, and control?

Source: Hereditary Angioedema 18. 5. 2022

News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.

Source: Diabetes 19. 4. 2022

News What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?

Allergic rhinitis, conjunctivitis, bronchial asthma, or autoimmune diseases like alopecia, vitiligo, celiac disease, and idiopathic inflammatory bowel diseases –⁠ these are comorbidities that often trouble patients with atopic dermatitis (AD). Modern systemic treatments bring new hope to these patients. "The primary benefit of targeted treatment, especially for severe AD, is the mitigation or elimination of chronic inflammation and persistent itching, significantly improving the quality of life for patients," says Chief Physician MUDr. Miroslav Nečas, Ph.D., from the 1st Department of Dermatovenereology of MU and St. Anne's University Hospital in Brno.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 26. 6. 2023

News Pegylated Liposomal Irinotecan + 5-FU/LV in the Treatment of mPDAC in Czech Clinical Practice –⁠ Results from the VILP Registry

At last year's annual congress of the European Society for Medical Oncology (ESMO) and this year's 15th PragueONCO, results from the Czech VILP registry were presented. This registry collected data on patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with pegylated liposomal irinotecan (nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV). The efficacy and safety of nal-IRI + 5-FU/LV in patients with mPDAC after failure or intolerance to gemcitabine-based chemotherapy, as found in the randomized controlled study NAPOLI-1, are thus confirmed in real clinical practice in the Czech Republic.

Source: Treatment of Gastrointestinal Carcinomas 25. 3. 2024

News Why can probiotics and vitamin D significantly affect human health?

Vitamin D deficiency is the most common hypovitaminosis in developed countries. It is largely related to a lack of outdoor activity. Additionally, the typical Western diet does not support a healthy composition of the gut microbiome. Gut dysbiosis, in turn, is associated with both intestinal and systemic diseases. Alongside a healthy lifestyle, probiotics and oral vitamin D supplementation offer solutions.

Source: GI, colic and microbiome 15. 3. 2022

News Quo vadis, erdostein? Or the current and future potential of erdosteine in practice

Erdosteine has a well-established place in the therapy of acute respiratory diseases in children. Its mucolytic and antibacterial properties are very well documented. Recently, research has focused primarily on the anti-inflammatory and antioxidant effects of this molecule. Attention is also being paid to its antiviral potential. How does it stand in this regard?

Source: Cough Therapy 15. 2. 2022

News Prediabetes through the lens of current data and findings −⁠ and why hurry with intervention

Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and mortality worldwide. The most serious impact on the health of the organism is mainly due to the macrovascular complications of this disease. However, their occurrence was often recorded before the diagnosis of DM2 was confirmed. Prediabetes itself thus represents a condition associated with the risk of developing cardiovascular (CV) complications with all their prognostic implications for patients.

Source: Diabetes 27. 7. 2022

News Current NCCN Recommendations for Classification and Risk Symptoms in SLL/CLL

The new recommendations from the National Comprehensive Cancer Network (NCCN) regarding chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) from August 2022 also include a brief summary of the most common symptoms and methods for classifying the disease based on its extent at diagnosis or in case of progression.

Source: Chronic Lymphocytic Leukemia 12. 1. 2023